SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Prometheus Biosciences, Inc. (RXDX) .
本页证实的标准:
- VALUE (10/100, 未通过) — 分析师共识目标价暗示当前价格存在下行风险 ($138.57, 30.7%).
- 分析师共识目标价 $138.57 (-30.7% 下行风险) — 分析师认为当前价格水平存在明显下行风险。
SharesGrow 综合评分： 36/100 其中 1/7 项标准通过。
SharesGrow 7-Criteria Score
✗
价值
10/100
Price-to-Earnings & upside
Proven by this page
✓
健康
100/100
Debt-to-Equity & liquidity
→ Health
估值概览 — RXDX
估值倍数
P/E (TTM)0.0
前瞻 P/EN/A
PEG 比率N/A
前瞻 PEGN/A
P/B 比率0.00
P/S 比率1,192.58
EV/EBITDA0.0
每股数据
EPS (TTM)$-3.49
每股账面价值$0.00
每股营收$0.17
每股自由现金流$0.00
收益率与内在价值
盈利收益率N/A
股息收益率0.00%
分析师目标价$138.57 (-30.7%)
P/E Ratio & Earnings Yield
每股收益 (EPS) 历史
| Year |
EPS（稀释） |
营收 |
净利润 |
净利润率 |
| 2015 |
$-2.18 |
$150K |
$-39.99M |
-26659.8% |
| 2016 |
$-3.44 |
$0.00 |
$-92.46M |
- |
| 2017 |
$-2.69 |
$0.00 |
$-103.64M |
- |
| 2020 |
$-1.13 |
$1.12M |
$-30.49M |
-2727.5% |
| 2021 |
$-1.13 |
$1.23M |
$-39.25M |
-3193.9% |
| 2022 |
$-2.87 |
$3.13M |
$-89.94M |
-2874.3% |
| 2023 |
$-3.49 |
$6.81M |
$-141.75M |
-2081.8% |
